Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deprenyl in Parkinson's disease

A J Lees, K M Shaw, L J Kohout

    Lancet (London, England)
    |October 15, 1977
    PubMed
    Summary

    (-)-Deprenyl, a selective MAO-B inhibitor, extended levodopa's benefits for Parkinson's patients, improving mild motor fluctuations. However, it did not help severe symptoms or depression and worsened dyskinesias in some.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Charcot redux.

    Brain : a journal of neurology·2025
    Same author

    Charcot's interest in faith healing.

    Journal of the history of the neurosciences·2024
    Same author

    The Dopamine Dancer: The Value of Holistic Autotherapy in Parkinson's Disease.

    Movement disorders clinical practice·2024
    Same author

    Copper rings, blue moons and sunflower cataracts.

    Arquivos de neuro-psiquiatria·2024
    Same author

    Earworms-A Narrative Review of Infectious Music.

    JAMA·2024
    Same author

    Reduced to a number.

    Practical neurology·2023

    Area of Science:

    • Neuroscience
    • Pharmacology
    • Movement Disorders

    Background:

    • Idiopathic Parkinson's disease (IPD) is a progressive neurodegenerative disorder.
    • Levodopa is a primary treatment for IPD, often combined with carbidopa.
    • Motor fluctuations ('on-off' effects) and dyskinesias are common challenges in levodopa therapy.

    Purpose of the Study:

    • To evaluate the efficacy of (-)-deprenyl as an adjunct to levodopa therapy in IPD patients.
    • To assess the impact of (-)-deprenyl on various motor symptoms, including 'on-off' disabilities and akinesia.
    • To determine if (-)-deprenyl allows for levodopa dose reduction and its effect on levodopa-induced side effects.

    Main Methods:

    • A double-blind, crossover trial involving 41 IPD patients on maximum levodopa doses.
    • (-)-Deprenyl administered at 10 mg daily or on alternate days.
    • Assessment of therapeutic effect duration, 'on-off' disabilities, akinesia, dyskinesias, and depression.

    Main Results:

    • (-)-Deprenyl prolonged levodopa's effect and improved mild 'on-off' disabilities and end-of-dose akinesia.
    • No significant improvement in diurnal akinesia or severe 'on-off' effects (freezing, 'yo-yo' effect).
    • Levodopa-induced dyskinesias worsened in 14 patients; depression remained unchanged.

    Conclusions:

    • (-)-Deprenyl may be beneficial for specific motor fluctuations in Parkinson's disease when combined with levodopa and a decarboxylase inhibitor.
    • It may allow for reduced levodopa dosage, potentially offering benefits comparable to higher levodopa doses.
    • Careful patient selection is needed due to potential worsening of dyskinesias and lack of effect on severe motor symptoms.

    Related Experiment Videos